Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Income from Continuing Operations (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Income from Continuing Operations for 4 consecutive years, with 5991000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 137.08% to 5991000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 52955000.0 through Dec 2025, up 13.11% year-over-year, with the annual reading at 52955000.0 for FY2025, 13.11% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 5991000.0 at Orchestra BioMed Holdings, up from 20828000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 5991000.0 in Q4 2025, with the low at 20828000.0 in Q3 2025.
  • Average Income from Continuing Operations over 4 years is 12252500.0, with a median of 13181500.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations crashed 125.14% in 2023, then surged 137.08% in 2025.
  • Over 4 years, Income from Continuing Operations stood at 9828000.0 in 2022, then decreased by 15.72% to 11373000.0 in 2023, then plummeted by 42.05% to 16155000.0 in 2024, then soared by 137.08% to 5991000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 5991000.0, 20828000.0, and 19363000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.